Pharmaceutical Raw Materials

Afatinib is an innovative anti-cancer target drug, that is, a new generation of oral target drug. It is the first anti-cancer target drug in the world that irreversibly combines with ErbB family (including four different epidermal growth factor receptors of cancer cells, such as EGFR, HER2, ERBB3 and ErbB4), so as to more effectively and specifically block the signal that triggers the growth of cancer cells, Reduce or delay the proliferation of cancer cells. Alfatinib has been approved as a first-line treatment drug in the United States, Europe and Taiwan for the treatment of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutant cancer cells. It is a daily oral target drug. Alfatinib was developed by German pharmaceutical company bringer Ingelheim. After a number of large-scale clinical trials, it was rated as a breakthrough treatment by FDA. The world authoritative academic journal nature also pointed out that "afatinib" has become one of the global positive headlines in 2013. Afatinib was listed in the United States and Europe in 2013, with the trade names of "gilotrif" and "giotrif" respectively; The Chinese trade names in Taiwan and Xiangkuang are "tuofuke" and "giotrif", respectively. The official use of the Chinese trade names is under review. By suppressing the signal transduction of ErbB family, it plays a key role in preventing tumor growth and proliferation. Alfatinib can irreversibly bind to ErbB family receptors, interrupt downstream information transmission, thus prevent cancer cell growth and induce apoptosis (programmed death). Therefore, compared with other target drugs, the irreversible binding of alfatinib to ErbB family receptors can provide more durable, selective, covalent and complete interruption of information transmission through cancer cells, thus bringing unique anti-cancer therapeutic benefits, more potential to inhibit the growth of a wide range of tumor cells, and more remarkable curative effect.

Pyridoxal phosphate is formed by the combination of vitamin B6 and phosphoric acid, including pyridoxal, pyridoxamine and pyridoxine. It exists in the form of phosphate ester in the body. Pyridoxal phosphate and pyridoxamine phosphate can be transformed into each other, and both of them are active. Pyridoxal phosphate is a coenzyme of aminotransferase and decarboxylase in amino acid metabolism, which can promote the decarboxylation of glutamic acid and promote the metabolism of glutamic acid γ- The formation of aminobutyric acid, which is a neurotransmitter. Pyridoxal phosphate, a coenzyme of citrulline and ornithine, is a drug used in the treatment of Parkinson's disease.

For the treatment of malaria, it can also be used for symptom suppression and prevention. Especially for the treatment and prevention of falciparum malaria caused by chloroquine resistant strains. It can also be used to treat silicosis.

This product is mainly used for pneumonia, bronchitis, pharyngitis, tonsillitis, pyelonephritis, urinary tract infection, gonococcal urethritis, cholecystitis, cholangitis, gynecological infection, sepsis and otitis media caused by Streptococcus, pneumococcus and other sensitive bacteria.

Ciprofloxacin hydrochloride is suitable for urinary tract infection, moderate and severe respiratory tract infection, intestinal infection, skin and soft tissue infection, sepsis and intraperitoneal infection caused by sensitive bacteria.